Medeon Biodesign, Inc. (TPEX:6499)
Taiwan · Delayed Price · Currency is TWD 73.70
+0.50 (0.68%)
Jun 18, 2026, 1:30 PM CST
Medeon Biodesign Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 431.84 | 419.43 | 292.81 | 196.26 | 298.32 | 68.96 | |
Revenue Growth (YoY) | 24.25% | 43.24% | 49.19% | -34.21% | 332.61% | -43.96% |
Cost of Revenue | 374.61 | 360.6 | 209.39 | 181.89 | 111.51 | 40.33 |
Gross Profit | 57.22 | 58.83 | 83.41 | 14.38 | 186.81 | 28.63 |
Selling, General & Admin | 205.79 | 194.08 | 203.75 | 185.91 | 153.03 | 108.35 |
Research & Development | 514.6 | 587.19 | 751.87 | 667.46 | 521.62 | 415.87 |
Operating Expenses | 720.65 | 781.34 | 969.03 | 853.94 | 674.65 | 524.22 |
Operating Income | -663.43 | -722.51 | -885.61 | -839.57 | -487.84 | -495.59 |
Interest Expense | -3.92 | -3.68 | -5.56 | -6.64 | -5.21 | -1.03 |
Interest & Investment Income | 6.64 | 7.19 | 20.17 | 19.94 | 10.29 | 6.12 |
Earnings From Equity Investments | - | - | - | 13.54 | 47.69 | 19.66 |
Currency Exchange Gain (Loss) | -3.59 | -2.6 | 14.43 | -6.19 | 15.35 | - |
Other Non Operating Income (Expenses) | 0.19 | 0.19 | 0.2 | 0.39 | 0.34 | -43.07 |
EBT Excluding Unusual Items | -664.11 | -721.42 | -856.37 | -818.53 | -419.38 | -513.91 |
Gain (Loss) on Sale of Investments | 0.15 | 1.72 | -2.28 | -399.15 | -19.73 | - |
Gain (Loss) on Sale of Assets | - | - | - | -13.01 | - | - |
Pretax Income | -663.96 | -719.69 | -858.64 | -1,231 | -439.12 | -513.91 |
Income Tax Expense | -0.06 | -0.35 | 11.88 | 39.29 | 57.79 | 72.46 |
Earnings From Continuing Operations | -663.9 | -719.34 | -870.52 | -1,270 | -496.9 | -586.36 |
Earnings From Discontinued Operations | - | - | - | - | - | 2,618 |
Net Income to Company | -663.9 | -719.34 | -870.52 | -1,270 | -496.9 | 2,031 |
Minority Interest in Earnings | 51.98 | 51.28 | 65.01 | 65.36 | 63.14 | 46.75 |
Net Income | -611.93 | -668.06 | -805.51 | -1,205 | -433.76 | 2,078 |
Net Income to Common | -611.93 | -668.06 | -805.51 | -1,205 | -433.76 | 2,078 |
Shares Outstanding (Basic) | 93 | 92 | 92 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 93 | 92 | 92 | 92 | 92 | 92 |
Shares Change (YoY) | 1.40% | 0.21% | 0.11% | 0.02% | -0.07% | 0.48% |
EPS (Basic) | -6.55 | -7.24 | -8.74 | -13.09 | -4.71 | 22.65 |
EPS (Diluted) | -6.55 | -7.24 | -8.74 | -13.09 | -4.71 | 22.65 |
Free Cash Flow | -563.5 | -645.61 | -906.97 | -810.36 | -601.91 | -301.69 |
Free Cash Flow Per Share | -6.03 | -6.99 | -9.84 | -8.80 | -6.54 | -3.28 |
Dividend Per Share | - | - | - | - | 0.476 | 0.794 |
Dividend Growth | - | - | - | - | -40.00% | - |
Gross Margin | 13.25% | 14.03% | 28.49% | 7.32% | 62.62% | 41.52% |
Operating Margin | -153.63% | -172.26% | -302.45% | -427.78% | -163.53% | -718.69% |
Profit Margin | -141.70% | -159.28% | -275.10% | -613.78% | -145.40% | 3013.75% |
Free Cash Flow Margin | -130.49% | -153.93% | -309.75% | -412.90% | -201.77% | -437.51% |
EBITDA | -608.91 | -666.44 | -839.21 | -797.3 | -459.64 | -463.09 |
EBITDA Margin | -141.00% | -158.89% | -286.61% | - | -154.08% | - |
D&A For EBITDA | 54.52 | 56.08 | 46.4 | 42.26 | 28.2 | 32.5 |
EBIT | -663.43 | -722.51 | -885.61 | -839.57 | -487.84 | -495.59 |
EBIT Margin | -153.63% | -172.26% | - | - | -163.53% | - |